Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test(R); Ocera Announces Preliminary Topline Results From Phase 2a of OCR-002 Print E-mail
By David Fowler   
Wednesday, 18 February 2015 20:30
Below is a look at some of .custom-msg { background:#fdffec; border: 1px solid #ffe594; color:#000000; text-align: center; font: 11px/14px Arial, Helvetica, sans-serif} the .kwd_bloack ul li{line-height:30px} headlines for companies that made news in the .kwd_bloack ul li a{float:left;width:510px;text-decoration:underline; font-size:24px; font-weight:bold; color:#ffb047; display:block; word-wrap: break-word; padding: 10px 0} healthcare sector on February 18, 2015.

Amarantus BioScience Holdings, Inc. (OTCQB:AMBS)
, a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of .custom-msg a { text-decoration: none; color:#CC0000; font-size: 11px} neurology, psychiatry, ophthalmology and regenerative medicine, and Anavex Life Sciences Corp. (Anavex) (OTCQX:AVXL), a biopharmaceutical company dedicated to
the .bottom_bg{height:44px; background:#181818; margin-top:34px} development of .custom-msg a:hover { text-decoration: underline} novel drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and Humspm.com various types of @media only screen and (max-width:960px), only screen and (max-device-width: 640px) and (min-device-width : 320px) cancer, today announced the .bottom_rs{width:960px; height:44px; overflow:hidden; margin:0 auto; position:relative} execution of a biomarker services agreement in which Amarantus will evaluate the .bottom_rs h3{float:left; width:auto; font-size:13px; color:#ababab; line-height:44px; text-transform:capitalize;padding-left:8px} pharmacodynamic effect of .container{width:100%} ANAVEX 2-73 and ANAVEX PLUS on the .bottom_rs ul{float:left; width:785px; height:44px; overflow:hidden;list-style:none} expression of .kwd_bloack{margin-top:0} the biomarker CD69 in specific sub-populations of .kwd_bloack ul{padding-bottom:20px} peripheral blood lymphocytes using Amarantus' proprietary Alzheimer's blood diagnostic LymPro Test®. In parallel, the companies have entered into a Letter of .header, .bottom_rs ul{height:auto} Intent ("LOI") for Amarantus to Related Links: assist Anavex in planning the .bottom_rs ul li{float:left; list-style:none; line-height:44px; padding-left:13px} scope of .leftblk{float:none; padding:0 5px} the blood-based biomarker components of .domain_name{line-height:33px; font-size:30px; float:left; width:74%; padding-top:29px; word-wrap:break-word} Anavex' next larger, potentially Phase 3, Alzheimer's disease clinical trial that is expected to Free Credit Report follow the .bottom_rs ul li a{float:left; font-size:16px; text-decoration:underline; color:#079ce9} ongoing Phase 2a study currently enrolling subjects to Cheap Air Tickets collect additional safety and exploratory efficacy data in mild to Online College Courses moderate AD patients.  Initial data from Anavex' Phase 2a AD trial is expected in the third quarter of .searchbox{margin:0; float:none; width:auto; padding:20px 5px} 2015.  ANAVEX 2-73 and ANAVEX PLUS, which combines ANAVEX 2-73 with donepezil (Aricept®), are Anavex' lead drug candidate and drug candidate combination, respectively, for Alzheimer's disease.

"We are pleased to assist Anavex, our first customer, in evaluating the potential of .kwd_bloack{float:none; width:auto; padding:0 5px} ANAVEX 2-73 and ANAVEX PLUS to increase CD69 expression using LymPro in blood derived from AD patients," said Gerald E. Commissiong, President & CEO of Amarantus. "Based on data generated in two previous peer-reviewed publications, our recently completed LP-002 clinical study, as well as studies presented by Amarantus in 2014 at the .kwd_bloack ul li a:hover, .bottom_rs ul li a:hover{color:#fff} Alzheimer Association International Conference, CD69 expression as measured by LymPro is decreased in patients with AD, as compared to

healthy controls and patients with confounding dementias. The ability of .srch-txt{width:65%} a new drug candidate to
increase CD69 expression, as measured by LymPro, may be indicative of .srch-btn{width:20%; float:left} a modification in the fundamental Alzheimer's disease process known as cell cycle dysregulation (a/k/a 'ectopic cell cycle re-entry'). Cell cycle dysregulation has been directly implicated as a key driver of .footerwrap{width:98%} the neuronal death in the areas of the brain affected by AD that is triggered by amyloid beta signaling through Tau. Our premier diagnostics division, Amarantus Diagnostics, is well positioned to add value to pharmaceutical companies' Alzheimer's therapeutics programs by helping them better execute AD therapeutic clinical studies. We will assist companies by enriching the population of #footer-keys-bot p {width:auto; height:auto; line-height:35px} subjects enrolling in Alzheimer's clinical studies, the key unmet need for therapeutic Alzheimer's programs, as well as evaluating drug activity of #footer-keys-bot{height:auto} cell cycle dysregulation, and potentially lipidomics and Amarantus Diagnotics Scientific Advisory Board.



 
==================================



Ocera Therapeutics, Inc. (Nasdaq:OCRX)
today announced preliminary topline results from a Phase 2a investigator-sponsored study evaluating the company's drug candidate OCR-002 (ornithine phenylacetate) versus placebo in patients with upper gastrointestinal bleeding (UGIB) associated with liver cirrhosis. The data demonstrated a favorable safety profile for OCR-002 and that the .sale-msg a:hover, .inquire a:hover{text-decoration: underline} drug candidate was well tolerated. The data also supported OCR-002's ability to reduce ammonia levels, elevated levels of which correlate with certain severe and #main-wrap{background:url(http://i1.cdn-image.com/__media__/pics/8243/bg.gif)} life-threatening liver disorders. In the study, an acute ammonia lowering effect in plasma, as well as higher urinary excretion of ammonia, was observed in patients treated with OCR-002 compared to placebo. The differences in plasma ammonia levels between treatment arms did not reach statistical significance, but the differences in urinary excretion of ammonia were statistically significant.

"Based on these topline data, we are encouraged by the #footer-keys-bot{text-align:center;background:#373045; border-bottom:2px solid #776e99; line-height:28px; padding:20px 0; word-wrap:break-word; -webkit-box-shadow: 0px 1px 10px 0px rgba(0,0,0,0.75); acute ammonia lowering effect and favorable safety profile demonstrated by OCR-002," stated Linda Grais, M.D., chief executive officer of
 
BMR:1